Meeting
2023 ASCO Annual Meeting
Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study.
Authors
Di Wu
Cancer Centre, The First Hospital of Jilin University, Changchun, China
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04979585
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9593)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9593
Abstract #
TPS9593
Poster Bd #
355b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
First Author: Mingfang Xu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Yonggui Hong
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara